News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
GroPep Limited Changes Track From Psoriasis Drug To Asthma
December 14, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Following poor efficacy in preclinical testing of its T-cell peptide drug candidate in psoriasis models, Adelaide biopharma GroPep (ASX:GRO) will undertake a market feasibility assessment for use of the drug in asthma.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Australia
MORE ON THIS TOPIC
Opinion
Evolving Market Pressures Force Biopharma Companies to Cut Assets Early
May 21, 2025
·
5 min read
·
Michael N. Abrams
Rare diseases
CRISPR Success in Single Baby Highlights Rare Disease ‘Crisis’
May 20, 2025
·
3 min read
·
Dan Samorodnitsky
Cardiovascular disease
Ionis Builds Triglyceride-Lowering Case for RNA-Targeting Tryngolza
May 20, 2025
·
2 min read
·
Tristan Manalac
Policy
The Memory Gap: How Forgotten Diseases Are Making a Dangerous Comeback
May 19, 2025
·
6 min read
·
Lori Ellis
